从价值医疗视角探讨晚期卵巢癌多腺苷二磷酸核糖聚合酶抑制剂维持治疗的用药选择  

Medication Selection of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors for Maintenance Therapy of Advanced Ovarian Cancer from the Perspective of Value Medical Treatment

作　　者：苏怡 杨国旺[2] 杨雯靖 SU Yi;YANG Guowang;YANG Wenjing(Graduate School of Beijing University of Chinese Medicine,Beijing 100105,China;Dept.of Oncology,Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China)

机构地区：[1]北京中医药大学研究生院,北京100105 [2]首都医科大学附属北京中医医院肿瘤科,北京100010

出　　处：《中国医院用药评价与分析》2023年第8期897-900,907,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家自然科学基金项目(No.82174453)。

摘　　要：目前,国内批准了4种多腺苷二磷酸核糖聚合酶(PARP)抑制剂用于晚期卵巢癌患者的维持治疗,药物可及性、可负担性得到极大改善。随着PARP抑制剂的广泛使用,临床医师面临着根据指南建议指导个体化临床实践的新挑战。本文从价值医疗视角(有效性、安全性、可及性)探讨了晚期卵巢癌PARP抑制剂维持治疗的用药选择,以期为临床用药提供指导。Four kinds of poly adenosine diphosphate ribose polymerase(PARP)inhibitors are currently approved in China for maintenance therapy of advanced ovarian cancer,and the drug accessibility and affordability have been greatly improved.With the widespread use of PARP inhibitors,clinicians have new challenges in guiding individualized clinical practice based on guideline recommendations.The thesis discusses the medication for PARP inhibitors maintenance therapy in advanced ovarian cancer from the perspective of value medical treatment(efficacy,safety and accessibility),with the aim of providing guidance for clinical medication.

关 键 词：价值医疗 多腺苷二磷酸核糖聚合酶抑制剂 晚期卵巢癌 维持治疗 

分 类 号：R979.1[医药卫生—药品]